Login to Your Account

U.S. Patent Disclosures

Monday, April 16, 2012
• Seaside Therapeutics Inc., of Cambridge, Mass., was granted U.S. Patent No. 8,143,311, titled "Methods of Treating Fragile X Syndrome and Autism." It covers the use of lead product GABA-B receptor agonist STX209 for the improvement of social and communication functions in autism.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription